These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26795874)

  • 41. Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.
    Shimura H; Saiko A; Hayashi A; Hattori N; Urabe T
    BMC Neurol; 2021 Feb; 21(1):61. PubMed ID: 33568083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
    Brawman-Mintzer O; Tang XC; Bizien M; Harvey PD; Horner MD; Arciniegas DB; Raskind M; Johnson-Greene L; Martineau RJ; Hamner M; Rodriguez-Suarez M; Jorge RE; McGarity S; Wortzel HS; Wei Y; Sindowski T; Mintzer J; Kindy AZ; Donovan K; Reda D
    J Neurotrauma; 2021 Jul; 38(14):1943-1952. PubMed ID: 33514274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
    De Cock VC; Dodet P; Leu-Semenescu S; Aerts C; Castelnovo G; Abril B; Drapier S; Olivet H; Corbillé AG; Leclair-Visonneau L; Sallansonnet-Froment M; Lebouteux M; Anheim M; Ruppert E; Vitello N; Eusebio A; Lambert I; Marques A; Fantini ML; Devos D; Monaca C; Benard-Serre N; Lacombe S; Vidailhet M; Arnulf I; Doulazmi M; Roze E
    Lancet Neurol; 2022 May; 21(5):428-437. PubMed ID: 35429481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
    Hauser RA; Cantillon M; Pourcher E; Micheli F; Mok V; Onofrj M; Huyck S; Wolski K
    Lancet Neurol; 2011 Mar; 10(3):221-9. PubMed ID: 21315654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
    Lewis G; Duffy L; Ades A; Amos R; Araya R; Brabyn S; Button KS; Churchill R; Derrick C; Dowrick C; Gilbody S; Fawsitt C; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Khan N; Lanham P; Pervin J; Peters TJ; Riozzie D; Salaminios G; Thomas L; Welton NJ; Wiles N; Woodhouse R; Lewis G
    Lancet Psychiatry; 2019 Nov; 6(11):903-914. PubMed ID: 31543474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin type B for gait freezing in Parkinson's disease.
    Fernandez HH; Lannon MC; Trieschmann ME; Friedman JH
    Med Sci Monit; 2004 Jul; 10(7):CR282-4. PubMed ID: 15232500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Rivastigmine Augmentation in Treatment of Male Patients With Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial.
    Rezaei Ardani A; Hosseini G; Fayyazi Bordbar MR; Talaei A; Mostafavi Toroghi H
    J Clin Psychopharmacol; 2017 Feb; 37(1):54-60. PubMed ID: 27930500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
    Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R
    BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rivastigmine does not alter cocaine-induced subjective effects or self-administration.
    Patel M; Verrico CD; De La Garza R
    Pharmacol Biochem Behav; 2019 Oct; 185():172758. PubMed ID: 31430484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial.
    Keshavrzi A; Rezaei H; Haghighi M; Jahangard L
    Neuropsychobiology; 2019; 78(4):200-208. PubMed ID: 31315114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.